AbFinder Therapeutics is focused on developing innovative biopharmaceutical platforms, specifically through its two main technologies: the PepFc® Platform and the AbFinder® Platform. The PepFc® Platform is a unique approach that utilizes Fc-replacing peptides, which are designed to enhance the therapeutic efficacy of biopharmaceuticals by improving their stability and bioavailability. This technology aims to address some of the limitations associated with traditional antibody therapies, potentially leading to more effective treatment options.

In addition, the AbFinder® Platform serves as an efficient antibody discovery and engineering system. This platform is designed to streamline the process of identifying and optimizing antibodies for therapeutic use, thereby accelerating the development of new biopharmaceuticals. By leveraging these advanced technologies, AbFinder Therapeutics aims to contribute to the next generation of biopharmaceuticals, focusing on innovative solutions that can improve patient outcomes in various therapeutic areas.

South Korea

AbFinder Therapeutics Co., Ltd. is a R&D company of biopharmaceutics based on innovative platform technologies including "PepFc® platform“, which is the one and only small peptide platform technology replacing Fc of IgG, and "AbFinder® platform“, which is a platform technology carrying out from discovering antibody therapeutics to engineering.

(14059) Room 730, LDC Biz tower, 47, Heungan-daero 427 beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do, South Korea

AbFinder Therapeutics

Company Details